1280 related articles for article (PubMed ID: 19703125)
1. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
[TBL] [Abstract][Full Text] [Related]
3. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
5. SPARC: a potential diagnostic marker of invasive meningiomas.
Rempel SA; Ge S; Gutiérrez JA
Clin Cancer Res; 1999 Feb; 5(2):237-41. PubMed ID: 10037170
[TBL] [Abstract][Full Text] [Related]
6. Caveolin-1 in meningiomas: expression and clinico-pathological correlations.
Barresi V; Cerasoli S; Paioli G; Vitarelli E; Giuffrè G; Guiducci G; Tuccari G; Barresi G
Acta Neuropathol; 2006 Nov; 112(5):617-26. PubMed ID: 16850311
[TBL] [Abstract][Full Text] [Related]
7. Patterns of SPARC expression and basement membrane intactness at the tumour-brain border of invasive meningiomas.
Schittenhelm J; Mittelbronn M; Roser F; Tatagiba M; Mawrin C; Bornemann A
Neuropathol Appl Neurobiol; 2006 Oct; 32(5):525-31. PubMed ID: 16972886
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
[TBL] [Abstract][Full Text] [Related]
9. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
[TBL] [Abstract][Full Text] [Related]
10. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
11. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
Miyagami M; Kanou T; Nakamura S
No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
[TBL] [Abstract][Full Text] [Related]
12. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
[TBL] [Abstract][Full Text] [Related]
13. Does protein expression predict recurrence of benign World Health Organization grade I meningioma?
Kärjä V; Sandell PJ; Kauppinen T; Alafuzoff I
Hum Pathol; 2010 Feb; 41(2):199-207. PubMed ID: 19801161
[TBL] [Abstract][Full Text] [Related]
14. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
[TBL] [Abstract][Full Text] [Related]
15. Expression of apoptotic and proliferation markers in meningiomas.
Konstantinidou AE; Pavlopoulos PM; Patsouris E; Kaklamanis L; Davaris P
J Pathol; 1998 Nov; 186(3):325-30. PubMed ID: 10211124
[TBL] [Abstract][Full Text] [Related]
16. [Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].
Korshunov AG; Shishkina LV; Golanov AV
Arkh Patol; 2002; 64(1):29-33. PubMed ID: 11889696
[TBL] [Abstract][Full Text] [Related]
17. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
18. Expression of extracellular matrix-degrading proteins in classic, atypical, and anaplastic meningiomas.
von Randow AJ; Schindler S; Tews DS
Pathol Res Pract; 2006; 202(5):365-72. PubMed ID: 16563650
[TBL] [Abstract][Full Text] [Related]
19. CD44 expression in human meningiomas: an immunohistochemical analysis.
Lewy-Trenda I; Omulecka A; Janczukowicz J; Papierz W
Pol J Pathol; 2004; 55(1):33-7. PubMed ID: 15195704
[TBL] [Abstract][Full Text] [Related]
20. Correlation of p63 immunoreactivity with tumor grade in meningiomas.
Rushing EJ; Olsen C; Man YG
Int J Surg Pathol; 2008 Jan; 16(1):38-42. PubMed ID: 18203782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
